Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Retained Earnings (2022 - 2025)

Historic Retained Earnings for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to -$46.5 million.

  • 60 Degrees Pharmaceuticals' Retained Earnings fell 2071.47% to -$46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.5 million, marking a year-over-year decrease of 2071.47%. This contributed to the annual value of -$40.5 million for FY2024, which is 2439.2% down from last year.
  • 60 Degrees Pharmaceuticals' Retained Earnings amounted to -$46.5 million in Q3 2025, which was down 2071.47% from -$44.1 million recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Retained Earnings peaked at -$28.8 million during Q4 2022, and registered a low of -$46.5 million during Q3 2025.
  • In the last 4 years, 60 Degrees Pharmaceuticals' Retained Earnings had a median value of -$36.3 million in 2024 and averaged -$37.0 million.
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Retained Earnings tumbled by 452.17% in 2024, and later plummeted by 3189.43% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Retained Earnings (Quarter) stood at -$28.8 million in 2022, then dropped by 13.07% to -$32.6 million in 2023, then fell by 24.39% to -$40.5 million in 2024, then decreased by 14.62% to -$46.5 million in 2025.
  • Its last three reported values are -$46.5 million in Q3 2025, -$44.1 million for Q2 2025, and -$42.4 million during Q1 2025.